Together, we’re shaping the future of cancer testing
Join us at Booth #29130 in Chicago from May 29 to June 2
See how we are transforming the way you detect cancer and help determine treatment plans. From prevention and earlier detection to treatment guidance and therapy selection, our portfolio of cancer diagnostic and screening tests help support you and your patients at every step of their care path.
We’re continually innovating to deliver the next wave of life-changing cancer solutions. Visit us at Booth #29130 during the 2026 ASCO® Annual Meeting to discover how our portfolio of products work together to strengthen precision treatment decisions.
Early detection
Treatment insights
Monitoring and therapy selection

Advancing molecular residual disease (MRD) detection: analytics and clinical evidence supporting the Oncodetect® test
Sunday, June 1 | 3:00-4:00 PM | McCormick Place, South Building | Level 3, Exhibit Hall, Theater 2
Join us as Dr. Rick Baehner and Dr. Jennifer Racz give an overview of the biological and technological foundations of MRD testing, including how the Oncodetect® test works and its analytical and clinical performance. We’ll explore next-generation MRD testing approaches such as whole-genome MAESTRO technology to detect MRD in solid tumors. Additionally, we’ll detail findings from the NSABP B-59 study and the PARTNER MRD sub-study, illustrating the evolving role of MRD testing in breast cancer management.
Abstracts of interest
Evaluation of whole-exome & whole-genome sequencing tumor-informed circulating tumor DNA MRD assays in patients with early triple-negative breast cancer (TNBC) receiving neoadjuvant chemotherapy (NAC) with or without olaparib: A prospective sub-study of the PARTNER trial.
Summary: Tumor-informed ctDNA MRD assessment using the Oncodetect whole-exome and whole-genome sequencing-powered tests demonstrating strong prognostic value in early triple-negative breast cancer, with post-operative ctDNA positivity highly predictive of distant recurrence following neoadjuvant chemotherapy. These findings reinforce the clinical potential of personalized MRD tests to refine risk stratification and guide treatment decisions, while expanded whole-genome approaches may further enhance detection sensitivity.
Session date & time: June 1, 1:30 PM
Characteristics of cancer patients undergoing molecular residual disease testing with a tumor-informed assay
Summary: In a large real-world cohort, tumor-informed ctDNA MRD testing with the Oncodetect test demonstrated that ctDNA positivity rates and cfDNA yield increase with disease stage across multiple cancer types, reinforcing its relevance as a biomarker of disease burden. Notably, integrated genomic profiling with the OncoExTra test, revealed a high prevalence of targetable alterations—regardless of ctDNA status—highlighting the potential to inform personalized treatment strategies and enable more timely therapeutic decisions.
Session date & time: June 1, 1:30 PM
Adenoma Detection Following Screening Colonoscopy and Stool-Based Colorectal Cancer Screening Tests with Follow-Up Colonoscopy: A Systematic and Network Meta-Analysis
Summary: This systematic review evaluated how effectively different colorectal cancer (CRC) screening strategies identify precancerous lesions (adenomas) at colonoscopy. Analyzing 47 U.S.-based studies of average-risk adults aged 45+, the study compared three pathways: primary screening colonoscopy, colonoscopy following a positive fecal immunochemical test (FIT), and colonoscopy following a positive multi-target stool DNA (mt-sDNA) test.
The findings show meaningful differences in adenoma detection rates across these approaches. Colonoscopy performed after a positive mt-sDNA test had the highest detection rate (~66%), followed by colonoscopy after a positive FIT (~51%), and screening colonoscopy alone (~34%).
These results suggest that stool-based screening are more likely to have detectable adenomas at follow-up colonoscopy. From a healthcare system perspective, this could allow optimizing colonoscopy resources , especially incapacity-constrained settings, by prioritizing patients who may benefit most.
Session date & time: TBD
AI-driven risk stratification for distant recurrence in node-positive ER+ /HER2- early breast cancer: Independent validation in the NSABP B-28 trial
Summary: An AI digital pathology-based risk score (RlapsRisk BC), previously validated in retrospective cohorts, is here shown to be highly prognostic for distant recurrence in women with node-positive ER+/HER2- early breast cancer in a randomized phase III cohort. Approximately two-thirds of N1 patients were classified as low risk and had excellent long-term outcomes on standard chemoendocrine therapy without CDK4/6 inhibitors. The study provides key independent validation of the tool and suggests it may be clinically useful for identifying node-positive ER+/HER2- patients who may be able to safely avoid treatment escalation with CDK4/6 inhibitors.
Session date & time: TBD
Neoadjuvant 21-gene Breast Recurrence Score redirects surgical and systemic treatment pathways in early breast cancer: a multicenter prospective study
Summary: Use of the Recurrence Score assay altered physicians’ treatment recommendations for 52% of women with HR+HER2- N0 early breast cancer in a small study (N = 76) from a consortium of hospitals in Quebec, Canada. The primary shifts were from neoadjuvant chemotherapy to upfront surgery (21.7%) and neoadjuvant endocrine therapy (21.7%). Associated drug costs and utilization[AM9.1] were also substantially reduced.
Session date & time: TBD
Role of neoadjuvant versus adjuvant chemotherapy, dose density, and treatment schedule in biologically high-risk HR+/HER2- breast cancer: a pooled analysis of the WSG ADAPT-HR+/HER2- and PlanB trials
Summary: In high-risk (Recurrence Score® result >25 OR N2-3) HR+HER2- early breast cancer, dose-dense (i.e., weekly) anthracycline- or paclitaxel-based regimens were inferior to extended, less frequent docetaxel-based chemotherapy for recurrence and survival. The authors also found no significant differences in recurrence and survival outcomes between neoadjuvant and adjuvant chemotherapy regimens and between anthracycline and non-anthracycline regimens.
Session date & time: TBD
Systemic cytokine dynamics during neoadjuvant chemotherapy versus endocrine therapy and CDK4/6 inhibition in high-risk luminal breast cancer: results from the GEICAM/2019-01-CARABELA trial
Summary: Pretreatment circulating levels of cytokines (markers of inflammation and angiogenesis) in women with HR+HER2- early breast cancer were not found to vary by Recurrence Score® result (RS ≤25 vs >25), indicating that cytokine levels are not indicators of genomic risk. However, increased cytokines after 12 weeks of chemotherapy were associated with a lack of tumor response to chemotherapy, indicating potential value in cytokine monitoring during treatment.
Session date & time: TBD
Prospective Evaluation of the Psychological Impact of Multicancer Early Detection (MCED) Blood Testing: A Smartphone-Based Patient Reported Outcomes Study
Summary: Real-world study from the Falcon registry evaluating anxiety and psychological impact of MCED testing using a digital platform
Session date & time: TBD
Cancer Recognition and Assessment through Non-invasive Evaluation (CRANE) – a prospective clinical validation study of a multi-biomarker class multi-cancer early detection (MCED) test in Japan
Summary: Prospective, case-control validation study evaluating the performance of the Cancerguard MCED test in a Japanese population
Session date & time: TBD
Beyond Detection: Five Year Screening Behaviors and Patient-Reported Perceptions in DETECT-A Participants
Summary: Five-year follow-up from the DETECT-A study evaluating patient experience, anxiety, and adherence to standard-of-care screening after MCED testing
Session date & time: TBD
Development of an Endometrial Cancer Test from a Vaginal Swab
Summary: A 4-MDM panel demonstrated high sensitivity for EC across all stages and types, supporting the potential for a non-invasive vaginal swab-based test to rule out endometrial cancer. Consistently high performance across patient subgroups suggests broad clinical utility. Future studies are necessary to finalize the panel and algorithm prior to validation.
Session date & time: June 1, 9:00 AM - 12:00 PM